Recurrent herpes simplex keratitis is a major cause of blindness in developed countries. I The destruction of corneal architecture results from reactivation of the herpes virus and the associated host inflamma tory responses. Currently available anti-viral drugs are potent inhibitors of active HSV-1 replication but are not capable of preventing and eliminating latent HSV-1 infection ? Vaccination strategies for protec tion against herpetic ocular disease and latency have Subunit vaccines consisting of purified HSV-1 envelope glycoproteins were effective in protecting animals against subsequent HSV-1 challenge when given prior to corneal HSV-1 inoculation. 12 , 1 3 HSV glycoprotein D (gD) is one of the dominant immunogens among the envelope glycoproteins of HSV. It plays an essential role in the attachment of HSV to the plasma membrane of cells and is critical to viral penetration into the cel1. 14 Furthermore, gD has a profound influence on both the humoral and cellular immune responses to HSV_l. IS We have previously shown that mice immunised subcutan eously with live HSV-1 virus or UV-inactivated virus are protected against keratitis and encephalitis. 16 We showed that immunisation with purified gD is effective in protecting animals against herpes simplex stromal keratitis, 17 and these findings were subsequently confirmed by others. 18
been explored for nearly three decades ? -8 Passive immunisation with monoclonal antibodies to herpes simplex virus glycoproteins 9 -11 has rekindled interest in polyvalent, subunit and recombinant vaccines for protection against HSV-l.
Subunit vaccines consisting of purified HSV-1 envelope glycoproteins were effective in protecting animals against subsequent HSV-1 challenge when given prior to corneal HSV-1 inoculation. 12 , 1 3 HSV glycoprotein D (gD) is one of the dominant immunogens among the envelope glycoproteins of HSV. It plays an essential role in the attachment of HSV to the plasma membrane of cells and is critical to viral penetration into the cel1. 14 Furthermore, gD has a profound influence on both the humoral and cellular immune responses to HSV_l. IS We have previously shown that mice immunised subcutan eously with live HSV-1 virus or UV-inactivated virus are protected against keratitis and encephalitis. 16 We showed that immunisation with purified gD is effective in protecting animals against herpes simplex stromal keratitis, 17 and these findings were subsequently confirmed by others. 18 Eisenberg et al. 19 showed that vaccinotherapy using synthetic peptides corresponding to the amino (N) terminal amino acid residues 1-23 of gD [gD(1-23)] or gD (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) protected mice against an intraperito neal or footpad challenge. 19 In the study reported here we investigated the influence of subcutaneous immunisation with gD(5-23) in a murine model of herpes simplex stromal keratitis. We tested the ability of this peptide to confer protection against herpes stromal keratitis and latent infection of the trigeminal ganglion. We compared divergent immunisation protocols for their protective potency and effect on the immune system.
MATERIALS AND METHODS

Mice
Male and female AIJ mice (IgH-1 e , H-2 a ) were obtained from the Jackson Laboratory (Bar Harbor, 
Vaccination Protocols
We compared five different immunisation protocols in the present study (Table I 
Clinical Scoring
The inoculated eyes were examined every other day for 14 days following HSV infection using a binocular surgical microscope. Latent Ganglionic HSV-l Infection On day 14 after corneal inoculation mice were killed by cervical dislocation and the trigeminal ganglia ipsilateral to the inoculated cornea were removed under sterile conditions, as previously described ? 8 Since immediate mincing reduces the viral shed ding, 29 we incubated the explanted ganglia. The ganglia were placed on Vero cell monolayers in 24 well plates (Falcon, Lincoln Park, NY) with 1 ml MEM containing S % fetal calf serum, 2 mM L glutamine, penicillin 100 Dlml and streptomycin 100 /-Lg/ml (all from Gibco) and incubated at 3rC in a humidified atmosphere with S% CO 2 for 3 weeks. The control wells on each plate contained uninfected Vero cell monolayers. The co-cultures were observed fo r cytopathological effects daily using inverted phase microscopy. Results of preliminary experi ments and of our prior work in this model 29 demonstrated that homogenised ganglia were nega tive for cytopathic effect on Vero cell monolayers for 21 days, showing the functional latency of this model and the lack of infectious virus in the ganglia at 14 days after corneal inoculation.
Statistics
Chi-squared analysis was used to analyse the significance of differences between the groups for the incidence of herpes simplex keratitis and the establishment of latent infection. The significance of differences in the means of the clinical scoring, virus neutralising titres and anti-HSV titres was deter mined by Fisher's protected test for least significant difference.
RESULTS
Protective Efficacy of gD(5-23) Against Herpetic Keratitis Subcutaneous injection of gD(S-23) or gD of HSV-1 prior to corneal infection with HSV-1 (F) reduced the incidence (p<O.OS) and severity (p<0.0001) of herpes simplex keratitis in A/J mice (Table II , Fig. 1 ). As shown in Table II , 12 of lS A/J mice injected with PBS,CFA developed stromal keratitis, confirming our previous findings in naive A/J mice p · 20 Only 4 of 16 A/J mice injected with gD prior to corneal HSV-1 infection developed stromal keratitis. The best protection against stromal keratitis was observed when mice were injected with gD(S-23) coupled to KLH and emulsified with adjuvant (p<O.OS). How ever, gD(S-23) had a protective capacity even when not coupled to this carrier protein, or when given without adjuvant (Table II, Fig. 1 ). The protection against ocular herpetic disease and encephalitis was similar when A/J mice were boosted twice using the same dosage of gD(S-23) (data not shown). A/J mice injected with either gD(S-23) or gD were completely protected against encephalitis, whereas 20% of the mice developed encephalitis when sham immunised (p<O.OS, Table II ).
Histopathology
The corneas of herpes stromal keratitis susceptible A/J mice injected with gD(S-23) had a normal appearance by day 14 after infection. Only a few mononuclear cells were found in the corneoscleral limbus , while neutrophils were completely absent. In Table II . All mice were immunised as described in Materials and Methods. Animals were followed for 2 weeks after inoculation with HSV-1 for signs of stromal keratitis and encephalitis. The table indicates Abbreviations as in Table i . contrast, A/J mice injected with the control vehicle had a marked accumulation of mononuclear cells and neutrophils in the limbus and in the cornea. The cornea was markedly oedematous, exhibiting a profound proliferation of fibrovascular tissue which was infiltrated with inflammatory cells (Fig. 2) .
Anti-HSV-I Neutralising Antibody Titres
Anti-HSV-l sera collected from AI] mice immunised with different injection protocols were tested for virus neutralisation (Table III) . The neutralising titre from A/J mice injected with gO was 1/100. The titres in mice injected with gO(5-23)-KLH were higher in those mice which received adjuvant (p<0.01). The free gD(5-23) failed to induce detectable neutralis ing antibody titres even when combined with adjuvant (p<0.000l).
Anti-gD Antibody Response
While no significant antibody tit res were observed in A. HEILIGENHAUS ET AL. Abbreviations as in Table I .
the PBS , CFA group, mice injected with gD(5-23) coupled to KLH had detectable titres of IgG , and IgG2a and low titres of IgG2b anti-HSV antibodies (p<O.05: Table IV) .
Latent Ganglionic Infection
In trigeminal ganglia of mice injected with the control vehicle. latent virus infection was found in 100% of the specimens, while virus was recovered from 50% of gO injected mice and from 50-75% of mice injected with free or KLH-coupled gO(5-23) (p<0.05; Table V) .
DISCUSSION
Herpes simplex virus susceptible AI] mice were injected subcutaneously with gO or gO(5-23) and the cornea subsequently challenged with HSV-l (F) in order to assess the protective efficacy against stromal keratitis and encephalitis. Our choice of this particular region of gO, namely the N-terminal HSV-l (F strain) animals were followed for 2 weeks ,t(Jr signs of stromal keratitis and scored on a scale of () to 4+. Further studies were undertaken to investigate whether immunisation with gO(5-23) prior to corneal infection influences the establishment of latent ganglionic infection and virus reactivation. Previous studies demonstrated that the adoptive transfer of virus neutralising or non-neutralising monoclonal anti-glycoprotein 0 antibodies'J ,11 failed to inhibit establishment of viral latency and epithelial keratitis completely , and the authors attributed this incomplete protection to the failure to induce cellular immunity. 11 Both gO( 5-23) and gO failed to provide complete protection against establishment of gang lionic latency in the present study , although cellular immunity was induced by immunising mice with gO(5-23). We can only speculate that ganglionic latency and epithelial keratitis might be affected through reduced primary infection, inhibition of viral replication, 40 absorption and penetration, 41 or impaired reactivation from latency.
Taken together. our data suggest that immunisa tion with a short peptide of gD of HSV-l confers protection against herpes stromal keratitis by anti HSV-l immune responses. Although the protection against acute keratitis was effective, the protection against ganglionic latency was incomplete, and this may result in recurrent keratitis over the long term.
A. HEILIGENHAUS ET AL.
A vaccine consisting of a mixture of peptides may be suitable for immunisation and may avoid viral resistance to the vaccine by point mutations. Whether immunisation with a short peptide of gO is sufficient to suppress virus reactivation and shedding and recurrent keratitis is yet to be studied.
